Goldman Sachs analyst Jason English upgraded WW to Buy from Neutral with a price target of $13, up from $3.80. The company’s subscriber base and earnings power has been shrinking, but a catalyst for a turnaround has emerged with its new obesity drug on-ramp solution, the analyst tells investors in a research note. The firm further states that WW will begin to offer a pharmaceutical based clinical subscription service that it can integrate with its legacy behavioral based weight management offering, and it expects a cohort of consumers to turn to it for help navigating what is poised to be an increasingly complex field of pharmaceutical solutions.
Published first on TheFly
See the top stocks recommended by analysts >>
Read More on WW:
- WW International Soars after Analyst Upgrade, Closes Sequence Acquisition
- WW International, Inc. Completes Acquisition of Sequence
- DA Davidson consumer products analyst to hold analyst/industry conference call
- Millennium discloses 5.1% passive stake in WW
- WW International, Inc. Announces Upcoming Changes to Board of Directors